Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells
Pegylation of biopharmaceuticals is the most common strategy to increase their half-life in the blood and is associated with a reduced immunogenicity. As antigen presentation is a primary event in the activation of CD4 T-cells and initiation of Anti-Drug Antibody (ADA) response, we investigated the...
Main Authors: | Marie de Bourayne, Sylvain Meunier, Samuel Bitoun, Evelyne Correia, Xavier Mariette, Hervé Nozach, Bernard Maillère |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.808606/full |
Similar Items
-
Certolizumab pegol – new option in the treatment of psoriatic arthritis
by: Maria Majdan, et al.
Published: (2014-07-01) -
EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
by: T. V. Korotaeva, et al.
Published: (2015-10-01) -
Certolizumab pegol in treatment of Crohn's disease with perianal lesions
by: I.L. Khalif, et al.
Published: (2018-04-01) -
Certolizumab pegol in treatment of Crohn's disease with perianal lesions
by: I L Khalif, et al.
Published: (2018-04-01) -
Certolizumab pegol in the treatment of spondyloarthritis
by: Mariusz Korkosz
Published: (2014-09-01)